MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week [Yahoo! Finance]
MediWound Ltd. (NASDAQ: MDWD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.